Novel anti-infective medical device

新型抗感染医疗器械

• 批准号: 971627
• 金额: $ 63.63万
• 依托单位: CLEAN BLUE LIMITED
• 依托单位国家: 英国
• 项目类别: Small Business Research Initiative
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=971627
• 关键词: Novel; anti; infective; medical; device

Over 100 million people use urinary catheters in the world every year. However, these devices are the root cause for the most common healthcare infection in the world, catheter-associated urinary tract infections (CAUTIs). CAUTIs serious enough to require antibiotic treatment affect 24% of long-term patients, of which ~70% of the bacteria responsible show antimicrobial resistance, resulting in ~ 2,100 deaths in the UK annually. CAUTIs are typically treated by long-term courses of antibiotics but this contributes to the spread of deadly antimicrobial resistant bacteria. Clean Blue Limited is developing the solution: a catheter that prevents colonisation of bacteria without using any pharmaceuticals in order to reduce the current dependency on antibiotic treatment and the subsequent risk of AMR occurrence. The successful development and application of this new technology could improve patient care; save lives and millions of pounds for the NHS; and open up a new front in the fight against antibiotic resistant bacteria

全世界每年有超过1亿人使用导尿管。然而，这些器械是世界上最常见的医疗保健感染（导管相关尿路感染）的根本原因。严重到需要抗生素治疗的尿路感染影响了24%的长期患者，其中约70%的细菌表现出抗菌素耐药性，导致英国每年约2，100人死亡。尿路感染通常通过长期抗生素治疗，但这有助于致命的抗菌素耐药细菌的传播。Clean Blue Limited正在开发解决方案：一种导管，可以在不使用任何药物的情况下防止细菌定植，以减少目前对抗生素治疗的依赖和随后发生AMR的风险。这项新技术的成功开发和应用可以改善患者护理;为NHS挽救生命和数百万英镑;并开辟了对抗抗生素耐药性细菌的新战线